Lilly is set to acquire Merida Biosciences for up to $2.875B, gaining a precision autoantibody-degrading platform led by ...
Marco Anelli, MD | Authors | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.
David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results